Gamida Cell Ltd (NASDAQ:GMDA) has earned an average recommendation of “Buy” from the eight brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $18.50.
GMDA has been the subject of several recent analyst reports. JMP Securities initiated coverage on Gamida Cell in a research report on Friday, September 20th. They issued an “outperform” rating and a $16.00 target price for the company. Oppenheimer set a $18.00 target price on Gamida Cell and gave the stock a “buy” rating in a research report on Wednesday, August 7th. ValuEngine raised Gamida Cell from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research cut Gamida Cell from a “buy” rating to a “hold” rating in a research report on Wednesday, October 9th.
Shares of NASDAQ GMDA traded up $0.05 during mid-day trading on Monday, reaching $4.90. The company had a trading volume of 2,900 shares, compared to its average volume of 24,441. The company has a current ratio of 4.47, a quick ratio of 4.47 and a debt-to-equity ratio of 0.23. The stock has a market cap of $120.14 million and a PE ratio of -0.47. The company has a 50-day moving average price of $4.65 and a two-hundred day moving average price of $5.23. Gamida Cell has a 1-year low of $2.93 and a 1-year high of $15.41.
Institutional investors have recently modified their holdings of the company. Rock Springs Capital Management LP acquired a new stake in shares of Gamida Cell in the second quarter worth $5,080,000. Noked Capital LTD acquired a new stake in shares of Gamida Cell in the second quarter worth $1,035,000. Royal Bank of Canada acquired a new stake in shares of Gamida Cell in the second quarter worth $71,000. Bank Hapoalim BM acquired a new stake in shares of Gamida Cell in the second quarter worth $195,000. Finally, EcoR1 Capital LLC acquired a new stake in shares of Gamida Cell in the second quarter worth $265,000. 25.70% of the stock is owned by institutional investors and hedge funds.
About Gamida Cell
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
Featured Article: Economic Reports
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.